Clinical Trial Update: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating oral GSK4172239D versus placebo in adults with sickle cell disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• GSK4172239D

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hematologic Diseases, Anaemia, Sickle Cell | Phase 1 | Status: TERMINATED